Modalis Therapeutics
Emerging biotech company that develops therapeutics using CRISPR based technology.
Launch date
Employees
Market cap
€27.4m
Enterprise valuation
€20m (Public information from Sep 2024)
Share price
JPY103 4883.T
Cambridge Massachusetts (HQ), Tokyo Japan (founding location)
Financials
Estimates*
| JPY | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 645m | 342m | 1.1m | 40.5m | - | 214m |
| % growth | - | (47 %) | (100 %) | 3582 % | - | - |
| EBITDA | 164m | (341m) | (1.2b) | (1.6b) | (2.3b) | - |
| % EBITDA margin | 25 % | (100 %) | (104567 %) | (3904 %) | - | - |
| Profit | 141m | (448m) | (739m) | (2.7b) | (2.4b) | - |
| % profit margin | 22 % | (131 %) | (67178 %) | (6673 %) | - | - |
| EV / revenue | - | 168.4x | 11651.8x | 168.8x | - | - |
| EV / EBITDA | - | -169.1x | -11.1x | -4.3x | -1.0x | - |
| R&D budget | 304m | 532m | 1.0b | 1.9b | 2.1b | - |
| R&D % of revenue | 47 % | 156 % | 91775 % | 4597 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$530k | Seed | ||
| N/A | JPY900m | Early VC | |
* | $4.2m | Series A | |
$15.0m | Series A | ||
$15.0m | Series B | ||
* | N/A | N/A | IPO |
| Total Funding | €37.9m | ||
Recent News about Modalis Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.